THERAtRAME
ULiège

THERAtRAME

Biotech
Biotech
Biotech
Biotech

THERAtRAME develops and positions new therapeutics targeting tRNA epitranscriptomics in cancer.

Cancer is the second most common cause of death worldwide. Even though great advances have been made in the last decades, the current therapeutic options are still poorly effective for a large portion of cancer patients. Poor response and development of resistance to therapy are the main cause of current cancer treatment failure, resulting in an urgent need for groundbreaking therapeutic solutions.

THERAtRAME has developed an innovative discovery platform to create and develop novel therapeutic agents to beat untreatable or resistant cancers. The company is building on the pioneering discoveries of its founders to develop first-in-class drugs targeting the tRNA epitranscriptomics. Their approach integrates hardcore drug discovery activities with unique proprietary screening technologies and AI-based mathematical models to exploit the potential of tRNA epitranscriptomics as a transversal target space in oncology.

No items found.

THERAtRAME is a spin-off company of the University of Liège (ULiège) and WELBIO that aims to translate the breakthrough discoveries made by its founders on the importance of tRNA epitranscriptomics in cancer into novel therapeutic strategies. This pioneering work results from over a decade of fundamental research performed at ULiège, with the support of WELBIO, the Belgian Foundation against Cancer and FNRS. The founder team was able to attract key business profiles and investors to guide the translation of its cutting-edge science into concrete solutions for the benefit of patients.

THERAtRAME has the ambition to become the world leader in providing and positioning new therapeutics against tRNA epitranscriptomics. Its unique platform approach has the potential to strongly contribute to major advances in cancer therapy by partnering with prominent pharma actors in oncology.

Sara Vandenwijngaert

Sara Vandenwijngaert

Investment Manager Qbic II & III

This company is aligned with the following SDGs

Good health and well-being
Good health and well-being
Gender equality
Gender equality
Aphea.Bio
Qbic II
Biotech
Biotech
Biotech
Biotech

Aphea.Bio

Aphea.Bio is developing the next generation of agricultural biologicals.

Universiteit Gent
Trince
Qbic II
Biotech
Biotech
Biotech
Biotech

Trince

Trince developed a new transfection technology based on a combination of laser light and photothermal nanoparticles.

Universiteit Gent
EyeD Pharma
Qbic II
Medtech
Medtech
Medtech
Medtech

EyeD Pharma

EyeD Pharma is developing micro-implants for drug release over a prolonged period of time.

ULiège